LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial

• DOI: 10.1016/j.annonc.2021.08.2085
• Publication Date: 2021-09-21T22:24:46Z
• Authors: N. Harbeck; U. Nitz; M. Christgen; S. Kuemmel; M. Braun; C.M. Biehl; C. Schumacher; W. Malter; B. Aktas; H. Forstbauer; J. Tio; E-M. Grischke; C. Kolberg-Liedtke; S. de Haas; R.J. Deurloo; R.E. Kates; C. Eulenburg zu; R. Wuerstlein; H. Kreipe; O. Gluz
• Keywords: Neoadjuvant Therapy